Search Results

Press Releases

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million

December 16, 2024

·

11 min read

Genetown

Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split

Pieris Pharmaceuticals, Inc. announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024.

April 19, 2024

·

4 min read

Genetown

Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential

Pieris Pharmaceuticals, Inc. provided a corporate update announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin® protein immuno-oncology assets partnered with Pfizer, Boston Pharmaceuticals, and Servier.

March 27, 2024

·

9 min read

Press Releases

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

July 24, 2024

·

22 min read

Genetown

Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that Stephen Yoder, president and chief executive officer of Pieris, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 a.m. ET in New York City.

June 2, 2023

·

1 min read

Business

Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring

Pieris Pharmaceuticals, Inc. today provided a strategic update following recent events that have impacted its inhaled respiratory franchise, including AstraZeneca’s discontinuation of enrollment of the Phase 2a study for elarekibep.

July 18, 2023

·

5 min read

Business

Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study

Pieris Pharmaceuticals, Inc. announced that partner AstraZeneca yesterday communicated to Pieris its decision to discontinue and cease dosing in the ongoing clinical studies of elarekibep.

June 21, 2023

·

4 min read

Business

Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, reported financial results for the quarter ended March 31, 2023, and provided a business update.

May 10, 2023

·

12 min read

Genetown

Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference

Pieris Pharmaceuticals, Inc. announced the presentation of preclinical data from the Company’s inhaled Jagged-1 targeting program, PRS-400, at the annual American Thoracic Society (ATS) International Conference being held in Washington, D.C. May 19-24, 2023.

May 22, 2023

·

5 min read

Drug Development

Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals’ Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals.

August 17, 2023

·

5 min read